CN115315256A - 用抗tigit拮抗剂抗体治疗癌症的方法 - Google Patents
用抗tigit拮抗剂抗体治疗癌症的方法 Download PDFInfo
- Publication number
- CN115315256A CN115315256A CN202180022830.2A CN202180022830A CN115315256A CN 115315256 A CN115315256 A CN 115315256A CN 202180022830 A CN202180022830 A CN 202180022830A CN 115315256 A CN115315256 A CN 115315256A
- Authority
- CN
- China
- Prior art keywords
- subject
- weeks
- dose
- subjects
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966448P | 2020-01-27 | 2020-01-27 | |
US62/966,448 | 2020-01-27 | ||
US202062985822P | 2020-03-05 | 2020-03-05 | |
US62/985,822 | 2020-03-05 | ||
US202062994272P | 2020-03-24 | 2020-03-24 | |
US62/994,272 | 2020-03-24 | ||
USPCT/US2020/024526 | 2020-03-24 | ||
PCT/US2020/024526 WO2021194481A1 (fr) | 2020-03-24 | 2020-03-24 | Dosage pour le traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1 |
US202063059054P | 2020-07-30 | 2020-07-30 | |
US63/059,054 | 2020-07-30 | ||
US202063059960P | 2020-07-31 | 2020-07-31 | |
US63/059,960 | 2020-07-31 | ||
US202063074827P | 2020-09-04 | 2020-09-04 | |
US202063074807P | 2020-09-04 | 2020-09-04 | |
PCT/US2020/049415 WO2022050954A1 (fr) | 2020-09-04 | 2020-09-04 | Dosage pour traitement avec anticorps antagonistes anti-tigit et anti-pd-l1 |
US63/074,807 | 2020-09-04 | ||
US63/074,827 | 2020-09-04 | ||
USPCT/US2020/049415 | 2020-09-04 | ||
US202063085890P | 2020-09-30 | 2020-09-30 | |
US63/085,890 | 2020-09-30 | ||
US202063105198P | 2020-10-23 | 2020-10-23 | |
US63/105,198 | 2020-10-23 | ||
US202063114517P | 2020-11-16 | 2020-11-16 | |
US63/114,517 | 2020-11-16 | ||
US202063124693P | 2020-12-11 | 2020-12-11 | |
US63/124,693 | 2020-12-11 | ||
US202063127109P | 2020-12-17 | 2020-12-17 | |
US63/127,109 | 2020-12-17 | ||
PCT/US2021/015143 WO2021154761A1 (fr) | 2020-01-27 | 2021-01-26 | Méthodes de traitement du cancer au moyen d'un anticorps antagoniste anti-tigit |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115315256A true CN115315256A (zh) | 2022-11-08 |
Family
ID=74626264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180022830.2A Pending CN115315256A (zh) | 2020-01-27 | 2021-01-26 | 用抗tigit拮抗剂抗体治疗癌症的方法 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4096646A1 (fr) |
JP (1) | JP2023511595A (fr) |
KR (1) | KR20220133243A (fr) |
CN (1) | CN115315256A (fr) |
AU (1) | AU2021212662A1 (fr) |
CA (1) | CA3165187A1 (fr) |
IL (1) | IL294800A (fr) |
MX (1) | MX2022009170A (fr) |
TW (1) | TW202142230A (fr) |
WO (1) | WO2021154761A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3181820A1 (fr) * | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methodes et compositions de traitement du cancer du sein triple negatif |
EP4363449A2 (fr) * | 2021-07-02 | 2024-05-08 | Genentech, Inc. | Méthodes et compositions pour le traitement du cancer |
WO2023010094A2 (fr) * | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Méthodes et compositions pour le traitement du cancer |
WO2023018675A1 (fr) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | Méthodes de traitement du cancer, d'une maladie infectieuse ou d'une infection à l'aide d'une combinaison d'un antagoniste de tigit, d'un antagoniste de pd -1 et de lenvatinib ou d'un sel pharmaceutiquement acceptable de celui-ci |
KR20240047393A (ko) * | 2021-08-10 | 2024-04-12 | 머크 샤프 앤드 돔 엘엘씨 | Tigit 길항제, pd-1 길항제 및 화학요법제(들)를 포함하는 치료 조합물 |
WO2023040804A1 (fr) * | 2021-09-14 | 2023-03-23 | 信达生物制药(苏州)有限公司 | Composition pharmaceutique d'anticorps anti-pd-1 et agent chimiothérapeutique et son procédé d'utilisation |
CN117940453A (zh) * | 2021-09-15 | 2024-04-26 | 江苏恒瑞医药股份有限公司 | 特异性结合pd-1的蛋白及其医药用途 |
WO2023122665A1 (fr) * | 2021-12-22 | 2023-06-29 | Genentech, Inc. | Formulations cliniques d'anticorps anti-tigit |
CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1993011161A1 (fr) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
JP3794701B2 (ja) | 1994-07-21 | 2006-07-12 | アクゾ ノーベル ナムローゼ フェンノートシャップ | 環状ケトン過酸化物処方 |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
EP1110953B1 (fr) | 1995-03-30 | 2009-10-28 | Pfizer Products Inc. | Dérivés de quinazolinone |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
DE69619114T2 (de) | 1995-07-06 | 2002-10-02 | Novartis Ag | Pyrolopyrimidine und verfahren zu ihrer herstellung |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
EP0892789B2 (fr) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Inhibiteurs irreversibles de tyrosine kinases |
AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
CN1195521C (zh) | 1997-05-06 | 2005-04-06 | 惠氏控股公司 | 喹唑啉化合物在治疗多囊肾病中的应用 |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
PL340800A1 (en) | 1997-11-06 | 2001-02-26 | American Cyanamid Co | Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps |
WO1999029888A1 (fr) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanisation d'anticorps murins |
CA2349721A1 (fr) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholine-4-yle-propoxy)-quinazoline-6-yle|-acrylamide, un inhibiteur irreversible des tyrosine kinases |
JP2008504809A (ja) | 2004-06-04 | 2008-02-21 | ジェネンテック・インコーポレーテッド | Egfr突然変異 |
DK2898329T3 (en) | 2012-09-24 | 2017-07-17 | Ventana Med Syst Inc | PROCEDURE FOR IDENTIFYING TREATMENT RESPONSIBLE NON-SMALL CELL LUNG CANCER USING ANAPLASTIC Lymphoma Kinase (ALK) AS MARKER |
LT3294770T (lt) | 2015-05-12 | 2020-12-28 | F. Hoffmann-La Roche Ag | Vėžio gydymo ir diagnostikos būdai |
MX2017014736A (es) | 2015-05-29 | 2018-03-23 | Genentech Inc | Metodos terapeuticos y diagnosticos para cancer. |
CA3092108A1 (fr) * | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosage pour traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1 |
-
2021
- 2021-01-26 JP JP2022545057A patent/JP2023511595A/ja active Pending
- 2021-01-26 KR KR1020227029306A patent/KR20220133243A/ko unknown
- 2021-01-26 IL IL294800A patent/IL294800A/en unknown
- 2021-01-26 TW TW110102913A patent/TW202142230A/zh unknown
- 2021-01-26 WO PCT/US2021/015143 patent/WO2021154761A1/fr unknown
- 2021-01-26 CN CN202180022830.2A patent/CN115315256A/zh active Pending
- 2021-01-26 EP EP21705841.1A patent/EP4096646A1/fr active Pending
- 2021-01-26 MX MX2022009170A patent/MX2022009170A/es unknown
- 2021-01-26 AU AU2021212662A patent/AU2021212662A1/en active Pending
- 2021-01-26 CA CA3165187A patent/CA3165187A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4096646A1 (fr) | 2022-12-07 |
WO2021154761A1 (fr) | 2021-08-05 |
TW202142230A (zh) | 2021-11-16 |
CA3165187A1 (fr) | 2021-08-05 |
IL294800A (en) | 2022-09-01 |
JP2023511595A (ja) | 2023-03-20 |
KR20220133243A (ko) | 2022-10-04 |
AU2021212662A1 (en) | 2022-08-11 |
MX2022009170A (es) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180346586A1 (en) | Methods of treating cancer using anti-ox40 antibodies | |
CN115315256A (zh) | 用抗tigit拮抗剂抗体治疗癌症的方法 | |
CA3038712A1 (fr) | Methodes therapeutiques et de diagnostic du cancer | |
EP3303397A1 (fr) | Méthodes destinées à traiter le cancer à l'aide d'anticorps anti-ox40 et d'antagonistes se liant à l'axe pd-1 | |
US20220016243A1 (en) | Methods for treatment of cancer with an anti-tigit antagonist antibody | |
US20210395366A1 (en) | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists | |
CA3151406A1 (fr) | Dosage pour traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1 | |
US20200171146A1 (en) | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent | |
US20230114626A1 (en) | Methods and compositions for treating triple-negative breast cancer | |
EP4143345A1 (fr) | Procédés et compositions pour l'immunothérapie du cancer du poumon non à petites cellules | |
TW202320848A (zh) | 治療癌症之方法及組成物 | |
WO2021194481A1 (fr) | Dosage pour le traitement avec des anticorps antagonistes anti-tigit et anti-pd-l1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |